A detailed history of Marshall Wace, LLP transactions in Cerus Corp stock. As of the latest transaction made, Marshall Wace, LLP holds 211,071 shares of CERS stock, worth $384,149. This represents 0.0% of its overall portfolio holdings.

Number of Shares
211,071
Previous 39,665 432.13%
Holding current value
$384,149
Previous $69,000 431.88%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.7 - $2.39 $291,390 - $409,660
171,406 Added 432.13%
211,071 $367,000
Q2 2024

Aug 14, 2024

SELL
$1.62 - $2.04 $263,919 - $332,342
-162,913 Reduced 80.42%
39,665 $69,000
Q1 2024

May 15, 2024

BUY
$1.66 - $2.42 $336,279 - $490,238
202,578 New
202,578 $382,000
Q4 2021

Feb 14, 2022

SELL
$5.97 - $7.93 $120,373 - $159,892
-20,163 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$4.79 - $6.68 $96,580 - $134,688
20,163 New
20,163 $123,000
Q2 2021

Aug 13, 2021

SELL
$5.35 - $6.35 $185,639 - $220,338
-34,699 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$5.68 - $7.87 $197,090 - $273,081
34,699 New
34,699 $209,000
Q3 2020

Nov 16, 2020

SELL
$5.78 - $7.47 $78,134 - $100,979
-13,518 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$4.5 - $7.02 $60,831 - $94,896
13,518 New
13,518 $89,000

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $322M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.